With the advent of next-generation sequencing technologies, genetic testing of prostate cancer patients is now typically done using multi-gene panels. These vary from targeted disease-specific panels to comprehensive (pan-cancer) panels, with advantages and disadvantages for each. This paper reviews a number of issues raised in choosing the best panels and labs to use, and issues presented by the increasing availability of direct-to-consumer testing.